Revenue
2019
2020
2021
2022
2023
2024
2025
2026
VITASPRING BIOMEDICAL CO. LTD. (VSBC)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2022
2023
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $5.6M | $248,200 | $15,140 | $17,180 | $16,230 | $0 |
| Gross profit | $0 | $0 | $0 | −$3.3M | $2.1M | $112,200 | $1,695 | $13,718 | $11,341 | $0 |
| Operating income | −$385,411 | −$679,914 | −$1.1M | −$4.2M | $1.1M | $425,382 | $6,919 | −$22,396 | −$6,374 | — |
| EBITDAderived | — | −$669,957 | −$1.1M | — | — | — | — | — | — | — |
| Net income | −$415,368 | −$774,922 | −$1.1M | −$4.2M | $909,560 | $425,382 | $6,919 | −$22,396 | −$6,374 | −$45 |
| Basic EPSper diluted share | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Diluted EPSper diluted share | $0.00 | $0.00 | -$0.01 | -$0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |